Oct 2, 2026
Neoadjuvant intratumoural immunotherapy: leveraging the primary tumour as a patient-specific in vivo vaccine site
Baldur Sveinbjørnsson, Chief Scientific Officer of Lytix Biopharma, has written an article for European Pharmaceutical Review, published on October 2, 2026.
The article explores how treating tumours before surgery may help stimulate a broader immune response. It discusses ruxotemitide (LTX-315), the Phase II NeoLIPA study, and implications for designing future trials of intratumoural immunotherapy.